# A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China

> **NCT06548568** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 110 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06548568
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548568, "A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06548568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*